Menu Back to DIA-Oligonucleotide-Based-Therapeutics-Conference


Call for Poster Abstracts
Abstract Submission Deadline EXTENDED: Monday, August 28
Details and Guidelines | Submit | Questions?

The DIA Oligonucleotide-Based Therapeutics Conference fosters open discussion with industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. Designed for regulators and industry from CMC, Nonclinical, Clinical Pharmacology, and Clinical disciplines, the conference will address developmental advances, safety, and challenges in the field of oligonucleotide-based therapeutics.

Insights Guide to Oligonucleotide-Based Therapeutics


  • Regulator, industry, and academic Panel Discussions
  • Poster Session
  • Networking Reception
  • Round Table Discussions

Call for Round Table Discussion Leaders, Deadline: August 25
Details and Guidlines | Submit

Check out our flyer for even more highlights and reasons to attend!

This is a very targeted meeting and a "must attend" for those developing drugs based on oligonucleotides. It is a multidisciplinary meeting that is well organized and has several new and challenging topics where industry and regulatory agency attendees participate with a view to enabling getting drugs to patients. 
-Previous Attendee

This program has been developed in collaboration with the DIA Oligonucleotide Scientific Working Group and is approved by the Regulatory Affairs Professionals Society for 12 RAC credits.

Who should attend?

Senior-level professionals and those working in the following areas of oligonucleotide science:

  • Biotechnology
  • Clinical Pharmacology
  • Clinical Research
  • Chemistry, Manufacturing, and Control
  • Clinical, Regulatory, and Business Development
  • Delivery Technologies
  • Drug Discovery
  • Preclinical
  • Quality Assurance
  • RNAi
  • Vaccines

Learning objectives

At the conclusion of this Conference, participants should be able to:

  • Identify accomplishments and challenges in the clinical development of oligonucleotide-based therapeutic drugs
  • Describe the critical issues in the nonclinical development of oligonucleotides
  • Differentiate the chemistry, manufacturing, and controls challenges associated with the development of synthetic oligonucleotides, including formulation and specification issues
  • Explain unique aspects and various scientific approaches used during the development of oligonucleotide-based therapeutics
  • Recognize the achievements made in the field to date and be able to share the vision with patients about the therapeutic potential that oligonucleotides possess across a wide range of indications
  • Discuss industry and regulatory agency efforts to partner and address the unmet medical needs of patients

Program Committee

  • James D. Thompson, PhD
    James D. Thompson, PhD Head, CMC Project Management
    Moderna Therapeutics, United States
  • James  Wild, PhD
    James Wild, PhD Pharmacologist, CDER
    FDA, United States
  • Paul C. Brown, PhD
    Paul C. Brown, PhD ODE Associate Director for Pharmacology and Toxicology, OND, CDER
    FDA, United States
  • Daniel  Capaldi, PhD
    Daniel Capaldi, PhD Vice President, Analytical and Process Development
    Ionis Pharmaceuticals, Inc., United States
  • Xuan  Chi, MD, PhD
    Xuan Chi, MD, PhD Pharmacologist/Toxicology Reviewer, Div. of Cardiovascular & Renal Products, OND
    US Food and Drug Administration, United States
  • Robert T. Dorsam, PhD
    Robert T. Dorsam, PhD Pharmacology/Toxicology Team Leader, Office of Generic Drugs, CDER
    FDA, United States
  • Scott  Henry, PhD
    Scott Henry, PhD Vice President, Nonclinical Development
    Ionis Pharmaceuticals, Inc., United States
  • Aimee L. Jackson, PhD
    Aimee L. Jackson, PhD Senior Director of Research
    miRagen Therapeutics, United States
  • Arthur M. Krieg, MD
    Arthur M. Krieg, MD President and CEO
    Checkmate Pharmaceuticals, United States
  • Arthur A. Levin, PhD
    Arthur A. Levin, PhD Executive Vice President, Research and Development
    Avidity NanoMedicines, United States
  • Jennifer  Marlowe, PhD
    Jennifer Marlowe, PhD Global Head, Translational Safety Models, Preclinical Safety
    Novartis Institutes For Biomedical Research, Inc., United States
  • Saraswathy  V. Nochur
    Saraswathy V. Nochur Senior Vice President, Regulatory Affairs & QA
    Alnylam Pharmaceuticals, Inc., United States
  • Emily J. Place, PhD, MPH
    Emily J. Place, PhD, MPH Pharmacologist, Office of New Drugs, CDER
    FDA, United States
  • Ramesh  Raghavachari, PhD
    Ramesh Raghavachari, PhD Chief, Branch I - DPMA1/OLDP/OPQ/CDER
    FDA, United States
  • Rosanne  Seguin, PhD
    Rosanne Seguin, PhD
    McGill University, Canada
  • Kim  Tyndall
    Kim Tyndall Director, CMC Regulatory Affairs
    GlaxoSmithKline, United States
Load More

Contact us

Customer Service


Insights Guide to Oligonucleotide-Based Therapeutics

Download Guide

Call for Poster Abstracts

Submit by August 28

Digital Learning Catalog

eLearning Catalog Cover